Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats☆
References (46)
- et al.
Effects of the β2-adrenoceptor agonist, clenbuterol, on muscle atrophy due to food deprivation in the rat
Metabolism
(1990) - et al.
Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone
Comp Biochem Physiol
(1992) - et al.
Clenbuterol, a β2-adrenergic agonist, reverses muscle wasting due to scald injury in the rat
Burns
(1993) - et al.
Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats
Metabolism
(1991) - et al.
β-Adrenergic receptors in innervated and denervated skeletal muscle
Biochim Biophys Acta
(1977) - et al.
The effect of β-agonists and antagonists on muscle growth and body composition of young rats
Comp Biochem Physiol
(1988) - et al.
Metabolic rate and thyroid status in rats fed diets of different protein-energy value: The importance of free T3
J Nutr
(1984) - et al.
Decreased myofibrillar protein breakdown following treatment with clenbuterol
J Surg Res
(1991) - et al.
Compartmental body analysis based on total-body nitrogen, potassium and calcium
Am J Physiol
(1980) - et al.
Muscle strength and speed of movement in relation to age and muscle morphology
J Appl Physiol
(1979)
Rehabilitation of the geriatric patient
Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue
Biochem J
Inhibition and reversal of denervation-induced atrophy by the β-agonist growth promoter, clenbuterol
Biosci Rep
Clenbuterol, a β2-agonist, retards atrophy in denervated muscles
Am J Physiol
Alpha actin and cytochrome c mRNA's in atrophied adult rat skeletal muscle
Am J Physiol
Aminohydroxybutane bisphosphonate and clenbuterol prevent bone changes and retard muscle atrophy respectively in tail-suspended rats
J Pharmacol Exp Ther
Modification of body composition by clenbuterol in normal and dystrophic mice
Biosci Rep
Muscle wasting associated with endotoxemia in the rat: Modification with the β2-adrenoceptor agonist clenbuterol
Biosci Rep
Denervation increases clenbuterol sensitivity in muscle from young rats
Muscle Nerve
Anabolic effects of clenbuterol on skeletal muscle are mediated by β2-adrenoceptor activation
Am J Physiol
Salbutamol in the 1980s: A reappraisal of its clinical efficacy
Drugs
Food intake, body and heart composition, and heart rate in T3 plus atenolol-treated rats
Am J Physiol
Cited by (48)
Simultaneous determination of fourteen β<inf>2</inf>-agonist enantiomers in food animal muscles by liquid chromatography coupled with tandem mass spectrometry
2022, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCitation Excerpt :β2-agonists, a large category of phenylethanolamine compounds (Fig. 1), are commonly used as bronchodilators in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in humans [1–3] and animals [4]. Some β2-agonists, such as CLE, SAL, TER, etc., have a significant nutritional redistribution function, which can promote the synthesis of muscle protein and reduce animal fat [5–8,36]. Thus, these drugs are illegally added to animal feeds to enhance growth rate and feed conversion.
Beta-2 agonists and exercise performance in humans
2010, Science and SportsCitation Excerpt :Relatively short periods (4–12 weeks) of specific beta-2 adrenergic agonists, especially clenbuterol and salmeterol, were shown to increase skeletal muscle strength and size in several animal species. In addition, this treatment, whether by oral intake or implanted osmotic minipumps, has been associated with a decline in body fat [10–13]. This anabolic effect on skeletal muscle has, however, never been found in either healthy animals or humans following oral salbutamol or terbutaline intake, possibly because of their short elimination half-life [14,15].
Salbutamol Improves Diaphragmatic Contractility in Chronic Airway Obstruction
2009, Archivos de BronconeumologiaAnabolic and lipolytic actions of beta<inf>2</inf>-agonists in humans and antidoping challenges
2020, Drug Testing and Analysis
- ☆
Supported by Veterans Administration Research Funds, Project No. 430-66-8721-0002.